Crystalline (3Z,5S)-5-(hydroxymethyl)-1-[(2′-methyl-1,1′-biphenyl-4-yl)carbonyl]pyrrolidin-3-one O-methyloxime, and methods of using the same
Crystalline (3Z,5S)-5-(hydroxymethyl)-1-[(2′-methyl-1,1-biphenyl-4-yl)carbonyl]pyrrolidin-3-one O-methyloxime is disclosed. A pharmaceutical composition containing the crystalline compound and methods for treating conditions related to the OT-R activity, such as preterm labor, and tor increasing embryo implantation rate in a mammal undergoing embryo transfer, comprising administering the crystalline compound are also disclosed.
1. Crystalline (3Z,5S)-5-(hydroxymethyl)-1-[(2′-methyl-1,1′-biphenyl-4-yl)carbonyl]pyrrolidin-3-one O-methyloxime, wherein said crystalline compound is characterized by an X-ray powder diffraction (XRPD) pattern substantially as illustrated in FIG. 1 .
2. Crystalline (3Z,5S)-5-(hydroxymethyl)-1-[(2′-methyl-1,1′-biphenyl-4-yl)carbonyl]pyrrolidin-3-one O-methyloxime, wherein said crystalline compound exhibits characteristic peaks at diffraction angle 2-theta degrees appearing at least at about 23.34, about 13.13, and about 7.05, as measured by XRPD.
3. Crystalline (3Z,5S)-5-(hydroxymethyl)-1-[(2′-methyl-1,1′-biphenyl-4-yl)carbonyl]pyrrolidin-3-one O-methyloxime, wherein said crystalline compound is characterized by a differential scanning calorimetry curve substantially as illustrated in FIG. 6 or FIG. 7 .
4. Crystalline (3Z,5S)-5-(hydroxymethyl)-1-[(2′-methyl-1,1′-biphenyl-4-yl)carbonyl]pyrrolidin-3-one O-methyloxime, wherein said crystalline compound is characterized by a thermo-gravimetric analysis curve substantially as illustrated in FIG. 8 or FIG. 9 .
5. A pharmaceutical composition comprising the crystalline compound of claim 2 and a pharmaceutically acceptable excipient.